The Danish drugstore, which became a high growth of the most valuable company in Europe, last year of the most valuable company in Europe, last year worth the sale of his Blockbuster Weight loss medicine, is confronted with a crucial moment while fighting the rising competition that the sale deucks. The company repeated its guidelines for the entire year, days after reducing its 2025 sales forecasts and replacing CEO Lars Fruildaard Jorgensen by veteran Insider Maziar Mike Doustdar. Market capitalization has since a peak has fallen to around $ 212 billion.
“We are taking measures to further sharpen our commercial implementation and to ensure efficiency in our cost basis while we continue to invest in future growth,” said the departing CEO Jorgensen in a statement. Doustdar will take over the helm on Thursday, confronting the company with difficult questions from investors about how it can remain competitive in the flourishing weight loss market for the American rival Eli Lilly and a wave of composite copycat versions.
Novo is hit by copycats from its GLP-1 drugs Wegovy for weight loss and ozempic for diabetes. American rights are pharmacies from replying approved medicines, but has made it possible to ‘compile’ for patients who need adapted doses or formulations.
NOVO reported the sale of the second quarter of 76.86 billion Danish crowns ($ 11.92 billion), an increase of 18% compared to last year, under the first expectations of analysts.
It confirmed a sales growth of 2025 between 8%and 14%, which was reduced in a profit warning last week compared to the previous 13%-21%. It was the second time this year that the company has reduced its sales forecast. The profit of the second quarter before interest and taxation (EBIT) was 33.45 billion crowns, an increase of 29% compared to a year ago.
#Wegovy #Maker #Novo #Nordisk #reduce #costs #billion #share #loss